Shots:

• 4D to receive up front in cash for each indication- ~$347.5M as option exercise fee- development & commercialization milestones with royalties on sales of licensed product derived from the collaboration. 4D has rights to cause MSD to purchase 4D shares for $5M during the first 12 mos. of the collaboration
• The agreement will combine 4D’s MicroRx platform with MSD’s expertise in the development and commercialization of vaccines for up to three indications and granting rights to MSD to develop- manufacture & commercialize vaccines following the exercise of any of its exclusive options
• 4D’s MicroRx platform rapidly interrogate library of bacterial isolates for therapeutic functionality either by identifying strains having a significant effect on the host or by targeting diseases which are driven by pathways matching the host response profile of the strain

Click here to­ read full press release/ article | Ref: 4D Pharma | Image: Pinterest